Precision Engineering of Nanobodies via Site-Specific Lysine Modification and KAT Ligation 24·04·2025
Cullinan Therapeutics Launches Phase 1 Trial of CD19 T Cell Engager CLN-978 for Rheumatoid Arthritis in Europe 18·04·2025